Jazz Pharmaceuticals (Germany) Investor Sentiment

J7Z Stock  EUR 116.85  1.15  0.97%   
Roughly 61% of Jazz Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Jazz Pharmaceuticals plc suggests that many traders are alarmed regarding Jazz Pharmaceuticals' prospects. The current market sentiment, together with Jazz Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Jazz Pharmaceuticals plc stock news signals to limit their universe of possible portfolio assets.
Jazz Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Jazz daily returns and investor perception about the current price of Jazz Pharmaceuticals plc as well as its diversification or hedging effects on your existing portfolios.
  
over six months ago at news.google.com         
Mackenzie Financial Corp Grows Position in Jazz Pharmaceuticals plc - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Jazz Pharmaceuticals Enters Oversold Territory - Yahoo Canada Shine On
Google News at Macroaxis
over six months ago at news.google.com         
Louisiana State Employees Retirement System Purchases Shares of 17,700 Jazz Pharmaceuticals plc - Ma...
Google News at Macroaxis
over six months ago at news.google.com         
Raymond James Financial Services Advisors Inc. Has 794000 Stock Position in Jazz Pharmaceuticals plc...
Google News at Macroaxis
over six months ago at news.google.com         
Jazz Pharmaceuticals is Now Oversold - Nasdaq
Google News at Macroaxis
over six months ago at news.google.com         
Mutual of America Capital Management LLC Decreases Stock Holdings in Jazz Pharmaceuticals plc - Defe...
Google News at Macroaxis
over six months ago at news.google.com         
Jazz Pharmaceuticals Hits New 1-Year Low at 111.11 - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Jazz Pharmaceuticals Hits New 12-Month Low at 111.11 - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Pharma Stock Roundup AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III - Zacks Investmen...
Google News at Macroaxis
over six months ago at news.google.com         
Braun Stacey Associates Inc. Trims Stake in Jazz Pharmaceuticals plc - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
JAZZ PHARMACEUTICALS PLC Trade Ideas BMVJAZZN TradingView - TradingView
Google News at Macroaxis
over six months ago at news.google.com         
Jazz Pharmaceuticals plc Sees Significant Increase in Short Interest - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
JAZZ PHARMACEUTICALS PLC Trade Ideas SWBJ7Z TradingView - TradingView
Google News at Macroaxis
over six months ago at news.google.com         
Nordea Investment Management AB Has 744000 Position in Jazz Pharmaceuticals plc - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Pacer Advisors Inc. Acquires 224,865 Shares of Jazz Pharmaceuticals plc - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Jazz Pharmaceuticals that are available to investors today. That information is available publicly through Jazz media outlets and privately through word of mouth or via Jazz internal channels. However, regardless of the origin, that massive amount of Jazz data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Jazz Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jazz Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jazz Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jazz Pharmaceuticals alpha.

Jazz Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Jazz Stock analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamental Analysis
View fundamental data based on most recent published financial statements